131 related articles for article (PubMed ID: 15727931)
61. Prostate secretory protein 94 inhibits sterol binding and export by the mammalian CAP protein CRISP2 in a calcium-sensitive manner.
El Atab O; Kocabey AE; Asojo OA; Schneiter R
J Biol Chem; 2022 Mar; 298(3):101600. PubMed ID: 35063506
[TBL] [Abstract][Full Text] [Related]
62. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum.
Weiss WA; Israel M; Cobbs C; Holland E; James CD; Louis DN; Marks C; McClatchey AI; Roberts T; Van Dyke T; Wetmore C; Chiu IM; Giovannini M; Guha A; Higgins RJ; Marino S; Radovanovic I; Reilly K; Aldape K
Oncogene; 2002 Oct; 21(49):7453-63. PubMed ID: 12386807
[TBL] [Abstract][Full Text] [Related]
63. Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3.
Van Eynde A; Litovkin K; Bollen M
Asian J Androl; 2011 Mar; 13(2):205-6. PubMed ID: 21102472
[No Abstract] [Full Text] [Related]
64. Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer.
Yeager M; Deng Z; Boland J; Matthews C; Bacior J; Lonsberry V; Hutchinson A; Burdett LA; Qi L; Jacobs KB; Gonzalez-Bosquet J; Berndt SI; Hayes RB; Hoover RN; Thomas G; Hunter DJ; Dean M; Chanock SJ
Hum Genet; 2009 Dec; 126(6):743-50. PubMed ID: 19644707
[TBL] [Abstract][Full Text] [Related]
65. Mouse models of prostate cancer.
Borowsky AD
Comp Med; 2003 Jun; 53(3):253-6. PubMed ID: 12868568
[No Abstract] [Full Text] [Related]
66. Genetically engineered murine models of prostate cancer: insights into mechanisms of tumorigenesis and potential utility.
Abdulkadir SA; Kim J
Future Oncol; 2005 Jun; 1(3):351-60. PubMed ID: 16556009
[TBL] [Abstract][Full Text] [Related]
67. MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.
Sutcliffe S; De Marzo AM; Sfanos KS; Laurence M
Prostate; 2014 May; 74(6):569-78. PubMed ID: 24464504
[TBL] [Abstract][Full Text] [Related]
68. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
Whitaker HC; Warren AY; Eeles R; Kote-Jarai Z; Neal DE
Prostate; 2010 Feb; 70(3):333-40. PubMed ID: 19790236
[TBL] [Abstract][Full Text] [Related]
69. Prostate cancer cell heterogeneity and plasticity: Insights from studies of genetically-engineered mouse models.
Li W; Shen MM
Semin Cancer Biol; 2022 Jul; 82():60-67. PubMed ID: 34147640
[TBL] [Abstract][Full Text] [Related]
70. Suggesting Tissue-Specific MSMB Gene Promoter as a Novel Approach for Prostate Targeted Gene Therapy.
Darayee M; Geramizadeh B; Tabei SMB; Rezvani A; Soleimanian S; Rahimi A
Asian Pac J Cancer Prev; 2022 Jun; 23(6):1993-2000. PubMed ID: 35763641
[TBL] [Abstract][Full Text] [Related]
71. Genetically defined mouse models that mimic natural aspects of human prostate cancer development.
Roy-Burman P; Wu H; Powell WC; Hagenkord J; Cohen MB
Endocr Relat Cancer; 2004 Jun; 11(2):225-54. PubMed ID: 15163300
[TBL] [Abstract][Full Text] [Related]
72. Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.
Arriaga JM; Abate-Shen C
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29661807
[TBL] [Abstract][Full Text] [Related]
73. Genetically engineered mouse models to study prostate cancer.
Brzezinska EA; Nixon C; Patel R; Leung HY
Methods Mol Biol; 2015; 1267():73-91. PubMed ID: 25636465
[TBL] [Abstract][Full Text] [Related]
74. Genetically engineered mouse models of prostate cancer.
Parisotto M; Metzger D
Mol Oncol; 2013 Apr; 7(2):190-205. PubMed ID: 23481269
[TBL] [Abstract][Full Text] [Related]
75. The current state of preclinical prostate cancer animal models.
Pienta KJ; Abate-Shen C; Agus DB; Attar RM; Chung LW; Greenberg NM; Hahn WC; Isaacs JT; Navone NM; Peehl DM; Simons JW; Solit DB; Soule HR; VanDyke TA; Weber MJ; Wu L; Vessella RL
Prostate; 2008 May; 68(6):629-39. PubMed ID: 18213636
[TBL] [Abstract][Full Text] [Related]
76. CaP CURE: Association for the Cure of Cancer of the Prostate.
Neoplasia; 2002; 4(4):369-71. PubMed ID: 12082553
[No Abstract] [Full Text] [Related]
77. Novel binders derived from an albumin-binding domain scaffold targeting human prostate secretory protein 94 (PSP94).
Marečková L; Petroková H; Osička R; Kuchař M; Malý P
Protein Cell; 2015 Oct; 6(10):774-9. PubMed ID: 26264490
[No Abstract] [Full Text] [Related]
78. Is 37LRP cell surface receptor for PSP94?
Pathak BR; Jagtap DD; Mahale SD
Asian J Androl; 2011 Mar; 13(2):347. PubMed ID: 21297657
[No Abstract] [Full Text] [Related]
79. New tools in therapeutic research--prostatic cancer and models.
Nyska A; Dayan A; Maronpot RR
Toxicol Pathol; 2002; 30(2):283-7. PubMed ID: 11950172
[No Abstract] [Full Text] [Related]
80. [Agreed on medical reports in prostate cancer. APInfo-Cap project].
Cózar-Olmo JM; Miñana-López B
Actas Urol Esp; 2012 Sep; 36(8):503-4. PubMed ID: 22819350
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
